Zevra TherapeuticsZVRA
ZVRA
About: Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Employees: 59
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
45% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 29
25% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 5 (+1) [Q1 2025]
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
1.95% more ownership
Funds ownership: 63.56% [Q4 2024] → 65.5% (+1.95%) [Q1 2025]
0% more funds holding
Funds holding: 109 [Q4 2024] → 109 (+0) [Q1 2025]
4% less capital invested
Capital invested by funds: $283M [Q4 2024] → $271M (-$11.6M) [Q1 2025]
46% less call options, than puts
Call options by funds: $2.76M | Put options by funds: $5.07M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$25
174%
upside
Avg. target
$25
174%
upside
High target
$25
174%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Kristen Kluska | 174%upside $25 | Overweight Reiterated | 14 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders
Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D.
Neutral
GlobeNewsWire
3 weeks ago
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees
ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change Board and Management Urge Stockholders to Follow Proxy Advisors' Recommendation and Vote “FOR” Wendy L. Dixon, Ph.D.
Neutral
Seeking Alpha
1 month ago
Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Nichol Ochsner - Vice President Neil McFarlane - President and Chief Executive Officer LaDuane Clifton - Chief Financial Officer Josh Schafer - Chief Commercial Officer Adrian Quartel - Chief Medical Officer Conference Call Participants Sumant Kulkarni - Canaccord Jason Butler - Citizens Eddie Hickman - Guggenheim Lachlan Hanbury - Brown with William Blair Operator Good afternoon and thank you for joining Zevra's First Quarter 2025 Financial Results and Corporate Update Conference Call. Today's call is being recorded, and will be available via the Investor Relations section of the company's website later today.
Negative
Zacks Investment Research
1 month ago
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.40 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025 Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025
Neutral
GlobeNewsWire
1 month ago
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism
CELEBRATION, Fla., April 17, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announces the publication of “Mechanistic insights into arimoclomol mediated effects on lysosomal function in Niemann-pick type C disease” in Molecular Genetics and Metabolism.
Neutral
GlobeNewsWire
2 months ago
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
CELEBRATION, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $150 million.
Neutral
GlobeNewsWire
2 months ago
Zevra Therapeutics Files Preliminary Proxy
Confirms Receipt of Two Director Nominees from Daniel J. Mangless Stockholders Are Not Required to Take Action at This Time CELEBRATION, Fla.
Neutral
Seeking Alpha
3 months ago
Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Nichol Ochsner - VP, IR and Corporate Communications Neil McFarlane - President and CEO LaDuane Clifton - CFO Joshua Schafer - Chief Commercial Officer and EVP, Business Development Adrian Quartel - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Jason Butler - Citizens JMP Sumant Kulkarni - Canaccord Oren Livnat - H.C. Wainwright Samantha Corwin - William Blair Eddie Hickman - Guggenheim Securities Operator Good afternoon, and thank you for joining Zevra's Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call.
Neutral
Zacks Investment Research
3 months ago
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.40 per share a year ago.
Charts implemented using Lightweight Charts™